Literature DB >> 10610746

Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.

A Capucci1, G Q Villani, D Aschieri, A Rosi, M F Piepoli.   

Abstract

AIMS: Direct current cardioversion of persistent atrial fibrillation is one of the most widely used and effective treatments for the restoration of sinus rhythm, but may be hampered by a low success rate and a high percentage of early recurrence. Pre-treatment with amiodarone or a glucose-insulin-potassium solution could improve the efficacy of electrical cardioversion by reversing the partially depolarized diastolic potential of the subsidiary pacemakers in atrial fibrillation. In a controlled randomized study, we assessed the effectiveness of electrical cardioversion in patients with persistent atrial fibrillation after pre-treatment with amiodarone or potassium infusion and the efficacy of amiodarone in maintaining sinus rhythm after electrical cardioversion. METHODS AND
RESULTS: Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg. day(-1)1 month before and 200 mg. day(-1)2 months after cardioversion), B (n=31, 180 mg. day(-1)oral diltiazem 1 month before and 2 months after cardioversion and 80 mmol potassium, 50 UI insulin in 500 ml 30% glucose solution 24 h before cardioversion) and C (n=30, control patients, 180 mg. day(-1)oral diltiazem 1 month before and 2 months after cardioversion). Before cardioversion all patients were under 4 weeks effective oral anticoagulant therapy (warfarin). Before electrical cardioversion, the rate of spontaneous conversion to sinus rhythm was higher in group A (25%) than groups B (6%) or C (3%) (P<0.005). Electrical cardioversion was more successful in group A (88%) than groups B (56%) or C (65%) (P<0.05), while the electrical thresholds for effective cardioversion were lower in group B than the other groups (P<0.05). Twenty-four hours after cardioversion, the early recurrence of atrial fibrillation was similar in the three groups (P=ns), while at 2 months the recurrence rate was lower in group A (32%) than groups B (56%) or C (52%) (P<0.01).
CONCLUSION: Pre-treatment with low-dose oral amiodarone, compared with oral diltiazem or glucose-insulin-potassium treatments, induces a significantly high percentage of instances of spontaneous conversion, increases electrical cardioversion efficacy and reduces atrial fibrillation recurrence. Copyright 2000 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10610746     DOI: 10.1053/euhj.1999.1734

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  24 in total

Review 1.  Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.

Authors:  Vincent E Hagens; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C van Gelder
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

Review 2.  Rhythm control and cardioversion.

Authors:  N Sulke; F Sayers; G Y H Lip
Journal:  Heart       Date:  2006-09-08       Impact factor: 5.994

3.  [Anti-arrhythmic drug therapy in impaired liver function].

Authors:  C Perings
Journal:  Internist (Berl)       Date:  2002-08       Impact factor: 0.743

4.  The outcome of direct current cardioversion (DCC) for the treatment of atrial fibrillation (AF) in a district general hospital in Ireland.

Authors:  K P O'Rourke; C Cotter; D Mullane; P Thorpe; P Sullivan
Journal:  Ir J Med Sci       Date:  2006 Apr-Jun       Impact factor: 1.568

5.  Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion.

Authors:  Ibrahim Altun; Burak Pamukcu; Cenk Eray Yildiz; Selda Can Arkaya; Goksel Guz; Akar Yilmaz; Ahmet Kaya Bilge; Umit Mutlu Turkoglu; Kamil Adalet
Journal:  Bosn J Basic Med Sci       Date:  2015-07-23       Impact factor: 3.363

6.  Prediction of the recurrence of atrial fibrillation after successful cardioversion with P wave signal-averaged ECG.

Authors:  Marco Budeus; Marcus Hennersdorf; Christian Perings; Heinrich Wieneke; Raimund Erbel; Stefan Sack
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

Review 7.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Atrial fibrillation: choosing an antiarrhythmic drug.

Authors:  Todd Rudo; Peter Kowey
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

Review 9.  Pharmacologic management of atrial fibrillation in the elderly: rate control, rhythm control, and anticoagulation.

Authors:  Seth McClennen; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2003-09       Impact factor: 2.931

Review 10.  [Pharmaceutical treatment of atrial fibrillation].

Authors:  Anil-Martin Sinha; Johannes Brachmann; Martin Schmidt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.